Federal Register / Vol. 75, No. 219 / Monday, November 15, 2010 / Notices 69685 

demonstrate evidence of its quality 

assessment and performance 

improvement program (QAPI) program 

for review by CMS. 

• To meet the requirements at 

§ 482.21(a)(1), DNVHC revised its 

standards to ensure QAPI is an ongoing 

program that shows measurable 

improvements in indicators for which 

there is evidence that it will improve 

health outcomes and identify and 

reduce medical errors. 

• To meet the requirements at 

§ 482.21(a)(2), DNVHC revised its 

standards to ensure the hospital’s QAPI 

program includes aspects of 

performance that assess process of care, 

hospital service, and operations. 

• To meet the requirements at 

§ 482.21(c)(2), DNVHC revised its 

standards to address the hospital’s 

responsibility to, among other things, 

implement preventive actions and 

mechanisms that include feedback and 

learning throughout the hospital as part 

of its performance improvement 

activities. 

• To meet the requirements at 

§ 482.21(d)(2), DNVHC revised its 

standards to clarify that a hospital may 

chose, as one of its quality initiatives, to 

develop and implement an information 

technology system to improve patient 

safety and quality. 

• To meet the requirements at 

§ 482.23(c), DNVHC revised its 

standards to ensure all drugs and 

biologicals are administered under the 

orders of a practitioner responsible for 

the care of the patient as specified at 

§ 482.12(c). 

• To meet the requirements at 

§ 482.23(c)(3), DNVHC revised its 

standards to include the requirement 

that blood transfusions and intravenous 

medications must be administered in 

accordance with State laws and 

approved medical staff policies and 

procedures. 

• To meet the requirements at 

§ 482.23(c)(4), DNVHC revised its 

standards to require blood transfusion 

reactions be reported immediately to the 

attending physician. 

• To meet the requirements at 

§ 482.30(a)(2), DNVHC revised its 

standards to address situations where 

CMS has determined that the utilization 

review (UR) procedures established by a 

State under title XIX of the Act are 

superior to those listed in 42 CFR part 

482, thus requiring hospitals in that 

State to meet the utilization control 

requirements at § 456.50 through 

§ 456.245 of this chapter of the 

regulations. 

• To meet the requirements at 

§ 482.30(c)(4) and § 482.30(e)(2), 

DNVHC revised its standards to require 

that the CAH review cases where the 

patient’s length of stay exceeds the 

mean length of stay for the applicable 

diagnostic-related group (DRG) and the 

hospitals charges for covered services 

exceed the DRG payment rate. 

• To meet the requirements at 

§ 482.30(d)(1)(i) through § 482.30(d)(3), 

DNVHC revised its standards to ensure 

determinations regarding admissions or 

continued stays are made by the 

practitioner responsible for the patient 

as specified in § 482.12(c). 

• To meet the requirements at 

§ 482.30(e)(ii), DNVHC revised its 

standards to require that the utilization 

review committee conduct a periodic 

review of each current inpatient 

receiving hospital services during a 

continuous period of extended duration 

for hospitals not paid under the 

prospective payment system. 

• To meet the requirements at 

§ 482.42(a)(2), DNVHC revised its 

standards to require the infection 

control officer maintain a log of 

incidents related to infections and 

communicable diseases. 

• To meet the requirements at 

§ 482.43(e), DNVHC revised its 

standards to require that the CAH 

periodically reevaluate its discharge 

planning process. 

B. Term of Approval 

Based on the review and observations 

described in section III. of this final 

notice, we have determined that 

DNVHC’s requirements for CAHs meet 

or exceed our requirements. Therefore, 

we approve DNVHC as a national 

accreditation organization for CAHs that 

request participation in the Medicare 

program, effective December 23, 2010, 

through December 23, 2014. 

V. Collection of Information 

Requirements 

This document does not impose 

information collection and 

recordkeeping requirements. 

Consequently, it need not be reviewed 

by the Office of Management and 

Budget under the authority of the 

Paperwork Reduction Act of 1995 (44 

U.S.C. 35). 

VI. Regulatory Impact Statement 

In accordance with the provisions of 

Executive Order 12866, this regulation 

was not reviewed by the Office of 

Management and Budget. 

Authority: Section 1865 of the Social 

Security Act (42 U.S.C. 1395bb). 

(Catalog of Federal Domestic Assistance 

Program No. 93.778, Medical Assistance 

Program) (Catalog of Federal Domestic 

Assistance Program No. 93.773, Medicare— 

Hospital Insurance; and Program No. 93.774, 

Medicare—Supplementary Medical 

Insurance Program). 

Dated: October 27, 2010. 

Donald M. Berwick, 

Administrator, Centers for Medicare & 

Medicaid Services. 

[FR Doc. 2010–28666 Filed 11–12–10; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Special Emphasis 

Panel for R01 Applications. 

Date: December 10, 2010. 

Time: 11 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Xiaodu Guo, MD, PhD, 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 761, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–4719, 

guox@extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Liver Ancillary 

Studies. 

Date: December 13, 2010. 

Time: 10 a.m. to 11:30 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Paul A. Rushing, PhD, 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 747, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–8895, 

rushingp@extra.niddk.nih.gov. 


srobinson on DSKHWCL6B1PROD with NOTICES
69686 Federal Register / Vol. 75, No. 219 / Monday, November 15, 2010 / Notices 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Innate Immunity 

and Experimental Crohn’s Disease. 

Date: December 17, 2010. 

Time: 10 a.m. to 12:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Paul A. Rushing, PhD, 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 747, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–8895, 

rushingp@extra.niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: November 8, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–28706 Filed 11–12–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director, National 

Institutes of Health; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

Recombinant DNA Advisory Committee. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Recombinant DNA 

Advisory Committee. 

Date: December 7–8, 2010. 

Time: December 7, 2010, 12 p.m. to 6 p.m. 

Agenda: The NIH Recombinant DNA 

Advisory Committee will review selected 

human gene transfer protocols, an 

application to certify a new host-vector 

system for K. lactis under Appendix I of the 

NIH Guidelines for Research Involving 

Recombinant DNA Molecules and discuss 

related data management activities. Please 

check the meeting agenda at http:// 

oba.od.nih.gov/rdna_rac/rac_meetings.html. 

Place: Hilton Washington/Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Time: December 8, 2010, 8 a.m. to 12:30 

p.m. 

Agenda: The NIH RAC will discuss 

selected human gene transfer protocols, and 

related data management activities. Please 

check the meeting agenda at http:// 

oba.od.nih.gov/rdna_rac/rac_meetings.html 

for more information. 

Place: Hilton Washington/Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: Chezelle George, Office of 

Biotechnology Activities, Office of Science 

Policy/OD, National Institutes of Health, 

6705 Rockledge Drive, Room 750, Bethesda, 

MD 20892. 301–496–9838. 

georgec@od.nih.gov. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

oba.od.nih.gov/rdna/rdna.html, where an 

agenda and any additional information for 

the meeting will be posted when available. 

OMB’s ‘‘Mandatory Information 

Requirements for Federal Assistance Program 

Announcements’’ (45 FR 39592, June 11, 

1980) requires a statement concerning the 

official government programs contained in 

the Catalog of Federal Domestic Assistance. 

Normally NIH lists in its announcements the 

number and title of affected individual 

programs for the guidance of the public. 

Because the guidance in this notice covers 

virtually every NIH and Federal research 

program in which DNA recombinant 

molecule techniques could be used, it has 

been determined not to be cost effective or 

in the public interest to attempt to list these 

programs. Such a list would likely require 

several additional pages. In addition, NIH 

could not be certain that every Federal 

program would be included as many Federal 

agencies, as well as private organizations, 

both national and international, have elected 

to follow the NIH Guidelines. In lieu of the 

individual program listing, NIH invites 

readers to direct questions to the information 

address above about whether individual 

programs listed in the Catalog of Federal 

Domestic Assistance are affected. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.14, Intramural Research 

Training Award; 93.22, Clinical Research 

Loan Repayment Program for Individuals 

from Disadvantaged Backgrounds; 93.232, 

Loan Repayment Program for Research 

Generally; 93.39, Academic Research 

Enhancement Award; 93.936, NIH Acquired 

Immunodeficiency Syndrome Research Loan 

Repayment Program; 93.187, Undergraduate 

Scholarship Program for Individuals from 

Disadvantaged Backgrounds, National 

Institutes of Health, HHS) 

Dated: November 5, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–28704 Filed 11–12–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Advisory Committee on Training in 

Primary Care Medicine and Dentistry 

AGENCY: Health Resources and Services 

Administration, HHS. 

ACTION: Notice of meeting cancellation. 

SUMMARY: Notice is hereby given of the 

cancellation of the Advisory Committee 

on Training in Primary Care Medicine 

and Dentistry, November 15, 2010, 8:30 

a.m. to 4:30 p.m., and November 16, 

2010, 8 a.m. to 2 p.m., at the Hilton 

Washington DC/Rockville Executive 

Meeting Center, 1750 Rockville Pike, 

Rockville, MD 20910, which was 

published in the Federal Register on 

October 19, 2010, FR Doc. 2010–26205 

(75 FR 64318). 

Dated: November 8, 2010. 

Robert Hendricks, 

Director, Division of Policy and Information 

Coordination. 

[FR Doc. 2010–28693 Filed 11–10–10; 4:15 pm] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control; Special 

Emphasis Panel: Epi-Centers for the 

Prevention of Healthcare-Associated 

Infections, Antimicrobial Resistance 

and Adverse Events, Funding 

Opportunity Announcement CI11–001; 

Initial Review 

Correction: This notice was published 

in the Federal Register on September 

14, 2010, Volume 75, Number 177, page 

55803. The location of the meeting has 

been changed to the following: 

Place: 12 Executive Park Drive, 

Atlanta, Georgia 30333. 

Contact Person for More Information: 

Gregory Anderson, M.S., M.P.H., 

Scientific Review Officer, CDC, 1600 

Clifton Road, NE., Mailstop E60, 

Atlanta, GA 30333, Telephone: (404) 

498–2293. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both CDC 

and the Agency for Toxic Substances 

and Disease Registry. 


srobinson on DSKHWCL6B1PROD with NOTICES